Breast cancer vaccines: Heeding the lessons of the past to guide a path forward
Cinzia Solinas1, Marco Aiello2, Edoardo Migliori3
1Azienda AUSL, Regional Hospital of Aosta, Aosta, Italy.
Abstract:
The ability of cancer immunotherapy to generate lasting responses in a broad spectrum of tumors has generated great enthusiasm in medical oncology. A number of new immune-based compounds have now been approved based on the recent success of immune checkpoint blockade, either administered as monotherapy or in combination with other agents. Because clinical activity is limited only to subsets of patients, two major goals of cancer immunotherapy are (1) to reliably identify responders to these current treatments, and (2) to increase the number of patients who can respond to immunotherapy by developing new strategies. These goals are critically important since the hallmark of immune-based therapies is the induction of durable immunologic and clinical responses that result in overall survival benefit. Innovative combination strategies have great potential for bringing the benefit of immunotherapy to more patients. The use of cancer vaccines to actively induce immune effectors together with other drugs, which may include immune checkpoint blockade, chemotherapy, and/or molecularly targeted agents, is a particularly attractive strategy. Cancer vaccines have been tested both to prevent or intercept the development of cancer, and to decrease established tumor burdens. No vaccine has yet been approved for either breast cancer treatment or prevention. Here, we review the history of breast cancer vaccine development, and highlight near-term opportunities for moving forward.
Insights
Cancer immunotherapy shows promise, but limited patient response necessitates new strategies. Breast cancer vaccines combined with other treatments offer a promising approach to improve patient outcomes and expand immunotherapy benefits.
Area of Science:
- Medical Oncology
- Immunology
- Vaccinology
Background:
- Cancer immunotherapy, particularly immune checkpoint blockade, has achieved significant success in treating various tumors.
- Current immunotherapies benefit only a subset of patients, highlighting the need for improved response identification and treatment expansion.
- Durable clinical and immunological responses are hallmarks of successful cancer immunotherapies, leading to improved overall survival.
Purpose of the Study:
- To review the historical development of breast cancer vaccines.
- To identify near-term opportunities for advancing breast cancer vaccine strategies.
- To explore innovative combination approaches to enhance immunotherapy efficacy in breast cancer.
Main Methods:
- Review of historical data and clinical trial outcomes for breast cancer vaccines.
- Analysis of combination strategies involving cancer vaccines with immune checkpoint blockade, chemotherapy, and targeted agents.
- Evaluation of vaccine applications in cancer prevention, interception, and treatment of established tumors.
Main Results:
- No cancer vaccine has yet received approval for breast cancer treatment or prevention.
- Combination strategies, including cancer vaccines, demonstrate potential for broader immunotherapy application.
- Vaccines aim to actively induce immune responses against cancer, complementing other therapeutic modalities.
Conclusions:
- Developing effective breast cancer vaccines remains a critical unmet need.
- Innovative combination therapies hold significant promise for increasing the number of patients benefiting from immunotherapy.
- Further research and strategic development are essential to advance breast cancer vaccine efficacy and application.
Related Concept Videos
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:59Cancer Prevention
Some...
01:27Tumor Immunotherapy
01:51Vaccinations
01:29Microorganisms in Medicine and Therapeutics
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...